About
About Sutro
Leadership
Leadership Team
Functional Leadership Team
Board of Directors
Scientific Advisory Board
Clinical Advisory Board
Collaborations
Corporate Presentation
Clinical Trials & CUA
Clinical Trials
Patient Resources
Commitment To Patients
Compassionate Use Access
Technology
iADCs & Antibody-Drug Conjugates
XpressCF+®
cGMP Facility
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
Governance
Pipeline
News
News Releases
Clinical / Scientific Presentation & Publication Highlights
Events
Events Audio Replays
Careers, Culture & DEIB
The Way We Work
Join Our Team
DEIB
DEIB Newsletter
Internships
Sutroites
Volunteer
Current Volunteer Newsletter
Contact Us
Search
Navigation
About
About Sutro
Leadership
Leadership Team
Functional Leadership Team
Board of Directors
Scientific Advisory Board
Clinical Advisory Board
Collaborations
Corporate Presentation
Clinical Trials & CUA
Clinical Trials
Patient Resources
Commitment To Patients
Compassionate Use Access
Technology
iADCs & Antibody-Drug Conjugates
XpressCF+®
cGMP Facility
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
Governance
Pipeline
News
News Releases
Clinical / Scientific Presentation & Publication Highlights
Events
Events Audio Replays
Careers, Culture & DEIB
The Way We Work
Join Our Team
DEIB
DEIB Newsletter
Internships
Sutroites
Volunteer
Current Volunteer Newsletter
Contact Us
Close
All SEC Filings
Investors
Investors
Overview
News & Events
Overview
News Releases
Events & Audio Replays
Email Alerts
Company Info
Overview
Management Team
Functional Leadership Team
Presentations
Contacts
FAQ
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
Analysts Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Filing Type:
View All
10-K
10-K/A
10-Q
3
4
424B4
424B5
8-A12B
8-K
ARS
CERT
CORRESP
CT ORDER
D
D/A
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
POS AM
POS EX
POSASR
PRE 14A
REGDEX
REGDEX/A
S-1
S-1/A
S-1MEF
S-3
S-3ASR
S-3MEF
S-8
SC 13D
SC 13G
SC 13G/A
UPLOAD
Year:
View All
2023
2022
2021
2020
2019
2018
2009
2007
2006
Date
Form
Description
PDF
XBRL
Pages
09/18/18
8-A12B
Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)
3
09/17/18
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
3
09/17/18
S-1/A
General form of registration statement for all companies including face-amount certificate companies
Documents
EX-1.1
EX-3.1
EX-3.2
EX-3.4
EX-5.1
EX-10.1
EX-10.4
EX-10.5
EX-10.11
EX-10.13
EX-10.15
EX-23.1
771
09/11/18
UPLOAD
SEC-generated letter
Documents
TEXT-EXTRACT
2
09/10/18
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
7
08/29/18
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
2
08/29/18
S-1
General form of registration statement for all companies including face-amount certificate companies
Documents
EX-3.1
EX-3.3
EX-4.1
EX-4.2(A)
EX-4.2(B)
EX-4.3
EX-4.4
EX-4.5
EX-10.2
EX-10.3
EX-10.6
EX-10.7
EX-10.8
EX-10.9
EX-10.10
EX-10.12
EX-10.14
EX-10.16
EX-21.1
EX-23.1
822
08/24/18
UPLOAD
SEC-generated letter
Documents
TEXT-EXTRACT
2
08/20/18
DRSLTR
Correspondence Related to Draft Registration Statement
3
08/08/18
D/A
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act.
6
Previous
1…
30
31
32
33
34
35
36
37
38
39
Next
Email Alerts
Contacts
RSS News Feed